Showing results (121-130 of 792) with videos related to
Sort By:
Pageof 80
Acta Diabetologica|December 12, 2024
The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trialsOliver Kuss, Michael Roden, Sabrina Schlesinger, et al.Deutsche Medizinische Wochenschrift (1946)|November 14, 2013
[Rare cause for severe hypertriglyceridemia - case 9/2013]Sabine Kahl, Michael Roden, Klaus Mörike, et al.Wiener Klinische Wochenschrift|January 7, 2006
Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitusMonika Lechleitner, Michael Roden, Eva Haehling, et al.Deutsche Medizinische Wochenschrift (1946)|February 1, 2019
[The Diabetic Heart and Heart Failure - Update on Mechanisms and Therapy]Elric Zweck, Julia Szendrödi, Malte Kelm, et al.Cell Metabolism|October 15, 2022
Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomesRevathi Sekar, Karsten Motzler, Yun Kwon, et al.Deutsche Medizinische Wochenschrift (1946)|February 16, 2021
[Acute metabolic complications in diabetes]Melina Mertens, Laura Dauben, Michael Roden, et al.Diabetes Care|September 22, 2019
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled TrialSabine Kahl, Sofiya Gancheva, Klaus Straßburger, et al.Psychosomatics|March 16, 2005
Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping stylesAymery Constant, Laurent Castera, Bruno Quintard, et al.Journal of Hepatology|December 3, 2014
Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasionNicolas Poté, François Cauchy, Miguel Albuquerque, et al.The Lancet Regional Health. Europe|July 17, 2025
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitisJeffrey V Lazarus, Paul N Brennan, Henry E Mark, et al.Pageof 80